» Articles » PMID: 11230986

Pivotal Role of Tyrosine Phosphatase SHP-1 in AT2 Receptor-mediated Apoptosis in Rat Fetal Vascular Smooth Muscle Cell

Overview
Journal Cardiovasc Res
Date 2001 Mar 7
PMID 11230986
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To examine the possible crosstalk and the roles of angiotensin (Ang) II type 1 (AT1) and type 2 (AT2) receptors in the control of apoptosis in fetal vascular smooth muscle cells (VSMCs).

Methods: Fetal VSMCs were prepared from rat fetal aorta at embryonic day 20. Expression of Ang II receptors was measured by a radioligand binding assay. Apoptotic changes were assessed by caspase 3 activity and chromatin dye staining. Regulation of extracellular signal-regulated kinase (ERK) activity via Ang II receptors was analysed by determining phosphorylated ERK with Western blot. Ang II receptor-mediated activation of tyrosine phosphatase SHP-1 was assessed by protein tyrosine phosphatase assay.

Results: The expression of AT1 and AT2 receptors was approximately 70%: 30% per cell. Serum depletion induced apoptosis in fetal VSMCs and selective AT1 receptor stimulation attenuated the apoptotic changes, whereas selective AT2 receptor activation enhanced apoptosis. Ang II increased ERK phosphorylation, which was inhibited by addition of the AT1 receptor-specific antagonist CV11974, but enhanced by addition of the AT2 receptor-specific antagonist PD123319, suggesting that activation of AT2 receptor attenuated the AT1 receptor-mediated ERK phosphorylation. Moreover, we demonstrated that AT2 receptor stimulation activated SHP-1 in fetal VSMCs, whereas AT1 receptor stimulation did not. Transient transfection of a dominant-negative SHP-1 mutant into rat fetal VSMCs resulted in a significant decrease of the AT2 receptor-mediated inhibition of ERK phosphorylation and attenuated the proapoptotic effect of AT2 receptor.

Conclusion: These results indicate that a crosstalk between AT1 and AT2 receptors regulates the survival of fetal VSMCs and substantiate SHP-1 as a key molecule in AT2 receptor signaling.

Citing Articles

The Angiotensin AT Receptor: From a Binding Site to a Novel Therapeutic Target.

Steckelings U, Widdop R, Sturrock E, Lubbe L, Hussain T, Kaschina E Pharmacol Rev. 2022; 74(4):1051-1135.

PMID: 36180112 PMC: 9553111. DOI: 10.1124/pharmrev.120.000281.


Class A and C GPCR Dimers in Neurodegenerative Diseases.

Caniceiro A, Bueschbell B, Schiedel A, Moreira I Curr Neuropharmacol. 2022; 20(11):2081-2141.

PMID: 35339177 PMC: 9886835. DOI: 10.2174/1570159X20666220327221830.


Angiotensin II Type 2 Receptor: A Target for Protection Against Hypertension, Metabolic Dysfunction, and Organ Remodeling.

Fatima N, Patel S, Hussain T Hypertension. 2021; 77(6):1845-1856.

PMID: 33840201 PMC: 8115429. DOI: 10.1161/HYPERTENSIONAHA.120.11941.


Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity.

Vallejo-Ardila D, Fifis T, Burrell L, Walsh K, Christophi C Oncotarget. 2018; 9(84):35500-35511.

PMID: 30464806 PMC: 6231452. DOI: 10.18632/oncotarget.26174.


Angiotensin II type 2 receptor inhibits expression and function of insulin receptor in rat renal proximal tubule cells.

Yang Y, Chen C, Fu C, Xu Z, Lan C, Zeng Y J Am Soc Hypertens. 2018; 12(2):135-145.

PMID: 29289466 PMC: 6389274. DOI: 10.1016/j.jash.2017.11.009.